D-enantiomeric peptides derived from D3 and use thereof

Patent metadata

Field	Value
Publication number	US-10167318-B2
Application number	US-201715482968-A
Country	US
Kind code	B2
Filing date	Apr 10, 2017
Priority date	Sep 14, 2012
Publication date	Jan 1, 2019
Grant date	Jan 1, 2019

Abstract

The present invention relates to novel D-enantiomeric A-beta-oligomer-binding peptides, homologs, fragments, parts and polymers thereof and use thereof.

First claim

What is claimed is:

1. A peptide comprising at least 50% D-enantiomeric amino acids and comprising at least one amino acid sequence selected from the group consisting of SEQ ID NO: 2 and homologs thereof having at least 83% sequence identity to SEQ ID NO: 2.

2. The peptide of claim 1 , wherein the at least one amino acid sequence is SEQ ID NO: 2.

3. The peptide of claim 1 , wherein the at least one amino acid sequence is a homolog of SEQ ID NO: 2 having at least 83% sequence identity to SEQ ID NO: 2.

4. The peptide of claim 1 , wherein the at least one amino acid sequence is a homolog of SEQ ID NO: 2 having at least 91% sequence identity to SEQ ID NO: 2.

5. The peptide of claim 1 , wherein the peptide is composed of D-amino acids.

6. The peptide of claim 1 , wherein the peptide comprises at least 80% D-enantiomeric amino acids.

7. The peptide of claim 1 , wherein the peptide comprises at least 90% D-enantiomeric amino acids.

8. The peptide of claim 1 , wherein the peptide comprises at least 95% D-enantiomeric amino acids.

9. The peptide of claim 1 , wherein the peptide is capable of inhibiting formation of fibrils of amyloid beta peptides.

10. The peptide of claim 1 , wherein the peptide is capable of binding to aggregated amyloid beta peptides.

11. The peptide of claim 1 , wherein the peptide is capable of being used as a therapeutic agent in medicine.

12. The peptide of claim 1 , wherein the peptide is capable of treating Alzheimer's disease.

13. A pharmaceutical composition, wherein the composition comprises as one of the components thereof the peptide of claim 1 .

14. A probe for the identification and quantitative and/or qualitative determination of amyloid beta fibrils and/or amyloid beta oligomers, wherein the probe comprises the peptide of claim 1 .

15. A kit, wherein the kit comprises the peptide of claim 1 .

16. The peptide of claim 1 , wherein the peptide is linked to a further substance.

17. A method for preparing the peptide of claim 1 , wherein the method involves peptide synthesis or mutagenesis.

18. A method of reducing the formation of amyloid beta oligomers and/or amyloid beta peptide aggregates in a patient in need thereof, wherein the method comprises administering to the patient the peptide of claim 1 .

19. A method for the detoxification of toxic amyloid beta oligomers and/or aggregates, wherein the method comprises contacting the oligomers and/or aggregates with the peptide of claim 1 .

20. The method of claim 19 , wherein the amyloid beta oligomers and/or aggregates form amorphous, non-toxic aggregates with the peptide.

Assignees

• Forschungszentrum Juelich Gmbh

Inventors

• Willbold Dieter
• Funke Susanne Aileen
• Brener Oleksander
• Nagel-Steger Luitgard
• Bartnik Dirk
• Klein Antonia Nicole

Classifications

• A61P25/28

  for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title

• C07K7/08 Primary

  having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68) · CPC title

• G01N33/6896 Primary

  Neurological disorders, e.g. Alzheimer's disease · CPC title

• C07K14/4711

  Alzheimer's disease; Amyloid plaque core protein · CPC title

• C07K7/06

  having 5 to 11 amino acids · CPC title